COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey

This study reports on 382 COVID-19 patients having undergone allogeneic ( n  = 236) or autologous ( n  = 146) hematopoietic cell transplantation (HCT) reported to the European Society for Blood and Marrow Transplantation (EBMT) or to the Spanish Group of Hematopoietic Stem Cell Transplantation (GETH...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Leukemia Ročník 35; číslo 10; s. 2885 - 2894
Hlavní autori: Ljungman, Per, de la Camara, Rafael, Mikulska, Malgorzata, Tridello, Gloria, Aguado, Beatriz, Zahrani, Mohsen Al, Apperley, Jane, Berceanu, Ana, Bofarull, Rodrigo Martino, Calbacho, Maria, Ciceri, Fabio, Lopez-Corral, Lucia, Crippa, Claudia, Fox, Maria Laura, Grassi, Anna, Jimenez, Maria-Jose, Demir, Safiye Koçulu, Kwon, Mi, Llamas, Carlos Vallejo, Lorenzo, José Luis López, Mielke, Stephan, Orchard, Kim, Porras, Rocio Parody, Vallisa, Daniele, Xhaard, Alienor, Knelange, Nina Simone, Cedillo, Angel, Kröger, Nicolaus, Piñana, José Luis, Styczynski, Jan
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: London Nature Publishing Group UK 01.10.2021
Nature Publishing Group
Predmet:
692/699/1541
692/699/255
Adolescent
Adult
Aged
Aged, 80 and over
Autografts
Cancer Research
Child
Child, Preschool
Coronaviruses
COVID-19
COVID-19 - complications
COVID-19 - virology
Critical Care Medicine
Diagnosis
Female
Follow-Up Studies
Graft-versus-host reaction
Hematologic Neoplasms - epidemiology
Hematologic Neoplasms - therapy
Hematologic Neoplasms - virology
Hematology
Hematopoietic Stem Cell Transplantation - methods
Hematopoietic stem cells
Humans
Immunodeficiency
Immunosuppression
Infant
Intensive
Internal Medicine
Male
Medicine
Medicine & Public Health
Middle Aged
Mortality
Multivariate analysis
Oncology
Prognosis
Prospective Studies
Respiratory tract
Respiratory tract diseases
Risk
SARS-CoV-2 - isolation & purification
Stem cell transplantation
Stem cells
Survival
Survival Rate
Transplantation
Transplantation, Homologous
Young Adult
Europe
ISSN:0887-6924, 1476-5551, 1476-5551
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:This study reports on 382 COVID-19 patients having undergone allogeneic ( n  = 236) or autologous ( n  = 146) hematopoietic cell transplantation (HCT) reported to the European Society for Blood and Marrow Transplantation (EBMT) or to the Spanish Group of Hematopoietic Stem Cell Transplantation (GETH). The median age was 54.1 years (1.0–80.3) for allogeneic, and 60.6 years (7.7–81.6) for autologous HCT patients. The median time from HCT to COVID-19 was 15.8 months (0.2–292.7) in allogeneic and 24.6 months (−0.9 to 350.3) in autologous recipients. 83.5% developed lower respiratory tract disease and 22.5% were admitted to an ICU. Overall survival at 6 weeks from diagnosis was 77.9% and 72.1% in allogeneic and autologous recipients, respectively. Children had a survival of 93.4%. In multivariate analysis, older age ( p  = 0.02), need for ICU ( p  < 0.0001) and moderate/high immunodeficiency index ( p  = 0.04) increased the risk while better performance status ( p  = 0.001) decreased the risk for mortality. Other factors such as underlying diagnosis, time from HCT, GVHD, or ongoing immunosuppression did not significantly impact overall survival. We conclude that HCT patients are at high risk of developing LRTD, require admission to ICU, and have increased mortality in COVID-19.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0887-6924
1476-5551
1476-5551
DOI:10.1038/s41375-021-01302-5